bispecific antibodies

J&J quietly punts a pair of early-stage bispecifics for solid tumors
J&J quietly punts a pair of early-stage bispecifics for solid tumors
Endpoints
JNJ
bispecific antibodies
solid tumors
Flag link:
FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate
FDA grants priority reviews for Pfizer's Prevnar 20 for kids and Roche lymphoma candidate
Endpoints
FDA
priority review
Pfizer
Prevnar 20
vaccines
Roche
bispecific antibodies
glofitamab
lymphoma
Flag link:
AbbVie's Roche-rivaling blood cancer bispecific gets FDA priority review, triggering Genmab payday
AbbVie's Roche-rivaling blood cancer bispecific gets FDA priority review, triggering Genmab payday
Fierce Biotech
AbbVie
Genmab
FDA
Roche
epcoritamab
bispecific antibodies
relapsed or refractory large B-cell lymphoma
Flag link:
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Fierce Pharma
Roche
Genentech
Vabysmo
bispecific antibodies
Eylea
Flag link:
Buy now, pay later: Jazz hands over $50M for Zymeworks' phase 3 HER2-directed bispecific
Buy now, pay later: Jazz hands over $50M for Zymeworks' phase 3 HER2-directed bispecific
Fierce Biotech
Jazz Pharmaceuticals
Zymeworks
HER2 inhbitor
bispecific antibodies
Flag link:
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
BioPharma Dive
Seagen
Merck
Lava Therapeutics
bispecific antibodies
LAVA-1223
Flag link:
J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering
J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering
Fierce Pharma
JNJ
Europe
bispecific antibodies
Multiple Myeloma
Tecvayli
teclistamab
Flag link:
Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets in light of data and competition
Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets in light of data and competition
Fierce Biotech
Amgen
BCMA
PSMA
Multiple Myeloma
bispecific antibodies
Flag link:
Following bispecific deal with Pfizer, quiet California biotech raises $65M, heads to the clinic
Following bispecific deal with Pfizer, quiet California biotech raises $65M, heads to the clinic
Endpoints
Dren Bio
Pfizer
bispecific antibodies
Flag link:
ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma
ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma
Pharmaforum
JNJ
Pfizer
ASCO 2022
bispecific antibodies
relapsed or refractory multiple myeloma
Flag link:
Roche trumpets new glofitamab data in lymphoma at ASCO
Roche trumpets new glofitamab data in lymphoma at ASCO
Pharmaforum
Roche
ASCO 2022
glofitamab
lymphoma
bispecific antibodies
Flag link:
Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs
Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs
MedCity News
Rondo Therapeutics
bispecific antibodies
solid tumors
cancer
funding
Flag link:
Roche looks to compete against a blockbuster with its newly approved vision drug
Roche looks to compete against a blockbuster with its newly approved vision drug
Stat
Roche
FDA
bispecific antibodies
Regeneron
Vabysmo
wet age-related macular degeneration
diabetic macular edema
Flag link:
Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies
Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies
BioSpace
Pfizer
Dren Bio
R&D
bispecific antibodies
Flag link:
J&J goes after another FDA approval for a cancer bispecific
J&J goes after another FDA approval for a cancer bispecific
Pharmaforum
JNJ
bispecific antibodies
cancer
FDA
Janssen
teclistamab
Multiple Myeloma
Flag link:
ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio
ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio
Endpoints
ASH2021
Roche
Genentech
bispecific antibodies
blood cancer
mosunetuzumab
Flag link:
J&J spends $100M upfront, with $1.2B in biobucks, to join Roche and Regeneron in bispecific blood cancer race
J&J spends $100M upfront, with $1.2B in biobucks, to join Roche and Regeneron in bispecific blood cancer race
Fierce Biotech
JNJ
Xencor
biobucks
Roche
Regeneron
bispecific antibodies
blood cancers
plamotamab
Flag link:
FDA starts review of Roche’s eye disease drug, setting up 2022 verdict
FDA starts review of Roche’s eye disease drug, setting up 2022 verdict
Pharmaforum
Roche
faricimab
bispecific antibodies
diabetic macular edema
wet age-related macular degeneration
Flag link:
Hemab raises $55M to target multiple rare bleeding indications
Hemab raises $55M to target multiple rare bleeding indications
Fierce Biotech
Hemab
funding
monoclonal antibodies
bispecific antibodies
Flag link:
Roche takes the Tim-3 battle to Novartis
Roche takes the Tim-3 battle to Novartis
EP Vantage
Roche
sabatolimab
Novartis
RG7769
bispecific antibodies
Flag link:

Pages